Kineret — CareFirst (Caremark)
Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
Reauthorization criteria
- Member achieves or maintains a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms, demonstrated by improvement in any of the following from baseline: fever, skin rash, joint pain and/or inflammation, central nervous system symptoms (e.g., meningitis, headache, cerebral atrophy, uveitis, hearing loss), or inflammatory markers (serum amyloid A, C-reactive protein, ESR).
Approval duration
12 months